Senomorphics

Senomorphics has been studied in 269 papers since 2018: 1 observational study in people, 5 in cells, 261 reviews; 135 in the past year. It has not reached trials in people. The newest paper, Nov 20, 2026: “Targeting accelerated kidney ageing in chronic kidney disease: from senolytics to Klotho therapeutics”.

InterventionPreclinical

269 papers study it47 findingsUpdated

Research on it is growing 96% faster than aging research as a whole: 186 papers in the latest year counted

More supplements

28 new papers in 30 daysSee all 269 papers on senomorphics

At a glance

Senomorphics decrease cellular senescence in human cells, a result independent labs reproduce, but a study reports increased senescence after pretreatment of well-decidualized cells. Reviews describe suppression of the senescence-associated secretory phenotype; a study in doxorubicin-treated engineered heart tissues reports no clear cardiac-function effect. Some papers declare company ties.

47 findings in 44 papers from 2019 to 2026, 17 of them since April 2026

The findings reach cells, none yet in people; independent labs found the same change in cells. 5 independent labs in 5 countries.

1 of its findings points the other way.

Cells: replicated by independent labs. Worms or flies, mice and humans: nothing yet.
  • 5 independent labs in 5 countries
  • 1 finding against
  • Funders: Avicenna Research Institute and others
  • 4 of 9 findings with company ties
  • Humans1
  • Cells5
  • In silico2

What did studies of senomorphics find?

13

Studies of senomorphics measured 13 outcomes; the most studied are senescence-associated secretory phenotype (SASP) (28 studies), cellular senescence (3) and osteoarthritis (2).

Senescence-associated secretory phenotype (SASP)

downin reviews27downin humans1

28 studies
  1. Senomorphics decrease senescence-associated secretory phenotype (SASP).

    Review

  2. Senomorphics inhibit senescence-associated secretory phenotype (SASP).

    Review

  3. Senomorphics decrease senescence-associated secretory phenotype (SASP).

    Review

  4. Senomorphics inhibit senescence-associated secretory phenotype (SASP).

    Review

  5. Senomorphics inhibit senescence-associated secretory phenotype (SASP).

    Review

  6. Senomorphics inhibit senescence-associated secretory phenotype (SASP).

    Review

  7. Senomorphics inhibit senescence-associated secretory phenotype (SASP).

    Review

  8. Senomorphics inhibit senescence-associated secretory phenotype (SASP) in humans.

    Reviewskin

  9. Senomorphics decrease senescence-associated secretory phenotype (SASP).

    Review

  10. Senomorphics inhibit senescence-associated secretory phenotype (SASP).

    Review

All 28

More on Senescence-associated secretory phenotype (SASP)

Cellular senescence

downin human cells3upin human cells1

3 studies
  1. Senomorphics decrease cellular senescence in human cells (UV-induced senescence in XP-derived melanocytes).

    CellsUV-induced senescence in XP-derived melanocytesmelanocyte

  2. Senomorphics increase cellular senescence in human cells (pretreatment in well-decidualized cells).

    Cellspretreatment in well-decidualized cells

  3. Senomorphics decrease cellular senescence in human cells (pretreatment in poorly-decidualized cells).

    Cellspretreatment in poorly-decidualized cells

  4. Senomorphics decrease cellular senescence in doxorubicin-treated dynamic engineered heart tissues.

    Cellsin doxorubicin-treated dynamic engineered heart tissuesheart

More on Cellular senescence

Osteoarthritis

downin mice1downin reviews1

2 studies
  1. Senomorphics protect against osteoarthritis (preclinical models).

    Reviewpreclinical models

  2. Senomorphics decrease osteoarthritis in murine models of OA.

    Reviewin murine models of OA

More on Osteoarthritis

Decidualization

upin human cells2

2 studies
  1. Senomorphics improve decidualization in senescent endometrial stromal cells; senomorphics rapamycin and metformin.

    Cellsin senescent endometrial stromal cells; senomorphics rapamycin and metformin

  2. Senomorphics improve decidualization in senescent ESCs.

    Cellsin senescent ESCsendometrium

SASP gene expression

downin human cells1

1 study
  1. Senomorphics decrease SASP gene expression in human cells (UV-induced senescence in XP-derived melanocytes).

    CellsUV-induced senescence in XP-derived melanocytesmelanocyte

More on SASP gene expression

Macrophage functions

upin human cells1

1 study
  1. Senomorphics improve macrophage functions in human cells (senomorphic treatment of senescent VSMCs before conditioned media transfer).

    Cellssenomorphic treatment of senescent VSMCs before conditioned media transfer

Secretion of senescence-promoting mediators

downin reviews1

1 study
  1. Senomorphics inhibit secretion of senescence-promoting mediators.

    Review

Disease progression

downin Rodentia1

1 study
  1. Senomorphics decrease disease progression in Rodentia.

    Review

Cardiac function

no changein human cells1

1 study
  1. Senomorphics showed no clear effect on cardiac function in doxorubicin-treated dynamic engineered heart tissues.

    Cellsin doxorubicin-treated dynamic engineered heart tissuesheart

Intervertebral disc degeneration

downin reviews1

1 study
  1. Senomorphics protect against intervertebral disc degeneration (degenerative diseases including IVDD).

    Reviewdegenerative diseases including IVDD

More on Intervertebral disc degeneration

All 13

What is senomorphics linked with?

2

Studies link senomorphics with 2 measures: senescence-associated secretory phenotype (SASP) and senolytics.

Senescence-associated secretory phenotype (SASP)

mixedin reviews1

1 study
  1. Senomorphics are associated with senescence-associated secretory phenotype (SASP) (without removing senescent cells).

    Reviewwithout removing senescent cellssenescent cells

More on Senescence-associated secretory phenotype (SASP)

Senolytics

no changein silico1

1 study
  1. Senolytics are associated with senomorphics in silico (comparison of physicochemical, structural and pharmacological properties).

    In silicocomparison of physicochemical, structural and pharmacological propertiesn = 84

More on Senolytics

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 8Jan 2026: 12Feb 2026: 5Mar 2026: 8Apr 2026: 8May 2026: 11Jun 2026: 11Jul 2026: 16Aug 2026: 6Sep 2026: 11Oct 2026: 22Nov 2026: 14132 papers in 12 months

See all 269 papers on senomorphics